Slides
Page 1
Q3 & 9M 2026 Results M il a n, October 29 th , 2 026
Page 2
Classification: public Disclaimer 2 The following applies to this document, the oral presentation of the information in this document by Amplifon S.p.A. (the “Company”), and any question-and-answer session that follows the oral presentation (collectively,the “Information”). In accessing the Information, you agree to be bound by the following terms and conditions. The Information is confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information contains forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future. No representation,warranty or undertaking,express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completenessor correctness of the Informationor the opinions contained therein. The Information has not been independentlyverified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward- looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward-looking statementsare based, or other events or circumstancesarising after the date of this document. This Informationdoes not constitutean offer to sell or the solicitationof an offer to buy the securities discussed herein. Statement In compliance with Article 154 bis of the “Uniform Financial Services Act” (Legislative Decree 58/1998), the Financial Reporting Officer, Gabriele Galli, declares that the accounting informationreported in this presentationcorrespondsto the underlyingdocumentaryreports, books of account and accounting entries. Non-IFRS and AlternativePerformanceMeasures This document contains certain AlternativePerformance Measures (APMs) used by managementto monitor the underlying economic, financial and operating performance of the Group, which are not defined by IFRS. Since the composition of such APMs is not regulated by the reference accounting principles, similarly entitled non-IFRS APMs reported by other companies may not be calculated in an identical manner and, consequently,may not be comparable. The APMs (i) are derived from historical results of Amplifon; (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited; and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APMs presented herein include EBITDA, EBITDA adjusted, EBIT adjusted, Profit before tax (PBT) adjusted, Net profit adjusted, Earnings per share (EPS) adjusted and Free Cash Flow. These APMs exclude the effect of unusual, infrequent or unrelated items to the normal course of business as the impact of these events might affect the understanding of the Group’s underlying performance. Definition of unusual, infrequent and unrelated items and reconciliationto IFRS Financial StatementsMeasures are provided in the Annex. Figures in the tables may reflect minimal differences exclusivelydue to rounding. © Amplifon S.p.A. October 29th, 2026
Page 3
Classification: public 3 Q3 2026 Highlights Another excellent quarter across the board. Strong momentum continues Revenues €575m +3.6% organic growth +0.2% at K FX EBITDA Adjusted €115m +7% vs Q3 2025 Margin at 20% +90 bps vs. Q3 2025 EBIT Adjusted €52m +22% vs. Q3 2025 Margin at 9.1% + 150 bps vs. Q3 2025 Free Cash Flow Adjusted €79m vs. 33m€ in 9M 2025 +139% vs. 9M 2025 Leverage1 1.85x NFP pro forma at €1,053m vs. €1,045m at YE25 supported by strong cash generation and after €128m in Capex and dividends © Amplifon S.p.A. October 29th, 2026 Net Profit Adjusted €27m +38.7% vs. Q3 2025 Margin at 4.6% + 120 bps vs. Q3 2025 1. Leverage pro forma as of September 30th, 2026, excluding the impact of the equity raise via ABB completed on May 22nd, 2026
Page 4
Classification: public 4 Q3 2026 Financial highlights Strong organic growth over the highest comparison base of the year. Substantial profitability improvement, supported by operating leverage and Fit4Growth Data in €m Q3 2026 Q3 2025 Δ% REVENUES 575.0 563.3 +2.1% Organic growth +3.6% Fit4Growth -3.9% M&A +0.5% FX +1.9% EBITDA Adjusted 114.8 107.3 +7.0% Margin % 20.0% 19.1% +90 bps Revenuegrowthat constantFX at +0.2% vs. Q3 2025 Strong organic growth at +3.6%, well-balanced across all Regions Continued positive momentum in global market demand - US private market growing strongly driven by a robust private pay segment,more than offsettinga still decreasinginsurancesegment - Positive market development in Europe and flattish in APAC Fit4Growth impact of -3.9% - Divesture of the UK business, termination of a managed care agreement in the US and closure of clinics globally (~30 in Q3 2026, >230 since launch) - Divesture of the dilutive business in India on August 12th, 2026 M&Acontributionof +0.5%, primarilyforcarryoverfrom2025bolt-ons FX tailwindmainlydrivenby USDandAUSD Adj. EBITDAof€114.8m,up+7.0%, withmarginat20%, up90bpsvs. Q3 2025 Excellent profitability improvement across all Regions Operatingleverage and strong results from Fit4Growth, also after ongoing investmentsto furtherstrengthenour distinctiveassets © Amplifon S.p.A. October 29th, 2026
Page 5
Classification: public 5 9M 2026 Financial highlights Strong organic growth and substantial improvement in profitability Revenuegrowthat constantFX at +0.9% vs. 9M 2025 Strong organic growth at +3.5%, balanced across all Regions Positive momentum in global market demand across all major geographic areas (US, EMEA and APAC) Fit4Growth impact of -3.3% - Divesture of the UK business, termination of a managed care agreement in the US and closure of clinics globally (>230 since launch) - Divesture of the dilutive business in India on August 12th, 2026 M&A contributionof +0.7%, primarilyfor carryoverfrom2025 bolt-ons NeutralFX reversingto positivein Q3 Adj. EBITDAof €412.8m, up +4.5%, with marginat 23.4%, up 80 bps vs. 9M 2025 Strong profitability improvement across all Regions Operatingleverage and strong results from Fit4Growth, also after ongoing investmentsto furtherstrengthenour distinctiveassets Data in €m 9M 2026 9M 2025 Δ% REVENUES 1,760.8 1,743.8 +1.0% Organic growth +3.5% Fit4Growth -3.3% M&A +0.7% FX +0.1% EBITDA Adjusted 412.8 395.0 +4.5% Margin % 23.4% 22.7% +80 bps © Amplifon S.p.A. October 29th, 2026
Page 6
Classification: public 6 Financial results by Region EMEA: Strong organic growth and excellent profitability improvement Revenuegrowthat constantFX at +1.0% vs. Q3 2025 Strong organic growth of +3.5% - Positivemarket development - Excellentperformancein SouthernEurope Fit4Growth impact of -2.7% - Divestureof the UK business and closure of clinics (~10 in Q3, ~100 since launch) M&A contributionof +0.2%, primarilyfor carryoverfrom 2025bolt-ons Adj. EBITDAof €88m,withmarginat 24.7%, up 140bpsvs. Q3 2025 Operatingleverage and strong results from Fit4Growth, also after ongoing investmentsto furtherstrengthenour distinctiveassets Revenuegrowthat constantFX at +1.0% vs. 9M 2025 Accelerating organic growth since Q2 Fit4Growth impact of -2.1% M&A at +0.4%, primarilyfor carryoverfrom 2025bolt-ons Adj. EBITDAat €324.4m,withmarginat 28.7%, up 140bpsvs. 9M 2025 Operating leverage and strong results from Fit4Growth, also after ongoinginvestmentsto furtherstrengthenour distinctiveassets Data in €m Q3 2026 Q3 2025 Δ% REVENUES 356.6 352.4 +1.2% Organic growth +3.5% Fit4Growth -2.7% M&A +0.2% FX +0.2% EBITDA Adjusted 88.0 82.2 +7.1% Margin % 24.7% 23.3% +140 bps Data in €m 9M 2026 9M 2025 Δ% REVENUES 1,132.4 1,118.3 +1.3% Organic growth +2.7% Fit4Growth -2.1% M&A +0.4% FX +0.3% EBITDA Adjusted 324.4 305.3 +6.3% Margin % 28.7% 27.3% +140 bps © Amplifon S.p.A. October 29th, 2026
Page 7
Classification: public Financial results by Region AMERICAS: Solid organic growth over the highest comparison base of the year, and substantial profitability improvement Revenueperformanceat constantFX at -3.8% vs. Q3 2025 Solid organic growth at +3.3% - US private market growing strongly driven by the private pay segment, offsettinga stilldecreasinginsurancesegment - HighestcomparisonbaseofFY25(+4.3% organicgrowthinQ3 2025vsQ3 2024) Fit4Growth impact of -8.6% - Termination of a managed care agreement in the US and closure of clinics (~40 since launch) M&A contribution of +1.5% - Carryoverfrom2025bolt-ons - Acquisitionof ~40 clinicsin Louisianain August,bringingthe Miracle-EarDirect Retailnetworkto ~450 clinics FX tailwind due to USD appreciation vs. EUR Adj. EBITDAof €26.0m, with marginat 21.4%, up 70 bps vs. Q3 2025 Operating leverage and strong results from Fit4Growth, also after ongoing investments to further strengthen our distinctive assets Revenueperformanceat constantFX at -1.4% vs 9M 2025 Very strong and above-market organic growth Fit4Growth impact of -8.2% M&A at +1.5%, primarilyfor carryoverfrom 2025 bolt-ons FX headwind decreasing throughout the period and reversing in Q3 Adj. EBITDAat €82.8m, with marginat 23.6%, up 110 bps vs. 9M 2025 Operating leverage and strong results from Fit4Growth, also after ongoing investments to further strengthen our distinctive assets Data in €m Q3 2026 Q3 2025 Δ% REVENUES 121.7 122.9 -1.0% Organic growth +3.3% Fit4Growth -8.6% M&A +1.5% FX +2.8% EBITDA Adjusted 26.0 25.5 +2.1% Margin % 21.4% 20.7% +70 bps Data in €m 9M 2026 9M 2025 Δ% REVENUES 350.4 366.0 -4.3% Organic growth +5.3% Fit4Growth -8.2% M&A +1.5% FX -2.9% EBITDA Adjusted 82.8 82.6 +0.3% Margin % 23.6% 22.6% +110 bps 7 © Amplifon S.p.A. October 29th, 2026
Page 8
Classification: public Financial results by Region APAC: Very strong organic growth and solid profitability improvement 8 Revenuegrowthat constantFX at +1.9% vs. Q3 2025 Very strong organic growth at +4.2% - Flattish market development - Excellentperformancein Australiaand China Fit4Growth impact of -2.5% - Closure of clinics (20 in Q3 2026, >90 since launch) - Divesture of the dilutive business in India on August 12th, 2026 M&A contributionof +0.2%, primarilyfor carryoverfrom 2025bolt-ons FX tailwind due to AUSD appreciation vs. EUR Adj. EBITDAof €23.9m, withmarginat 24.8%, up 50 bpsvs. Q3 2025 OperatingleverageandstrongresultsfromFit4Growth,evenafterfastgrowth of Chinaandongoinginvestmentsto furtherstrengthenourdistinctiveassets Revenuegrowthat constantFX at +3.6% vs. 9M 2025 Strong organic growth of +4.4% Fit4Growth impact of -1.3% M&A at +0.5%, primarilyfor carryoverfrom 2025bolt-ons FX tailwind reversing since Q2 Adj. EBITDAat €71.7m, with marginat 25.8%, up 70 bps vs. 9M 2025 OperatingleverageandstrongresultsfromFit4Growth,evenafterfastgrowth of Chinaandongoinginvestmentsto furtherstrengthenourdistinctiveassets Data in €m Q3 2026 Q3 2025 Δ% REVENUES 96.7 88.0 +9.9% Organic growth +4.2% Fit4Growth -2.5% M&A +0.2% FX +8.0% EBITDA Adjusted 23.9 21.4 +12.1% Margin % 24.8% 24.3% +50 bps Data in €m 9M 2026 9M 2025 Δ% REVENUES 278.0 259.5 +7.1% Organic growth +4.4% Fit4Growth -1.3% M&A +0.5% FX +3.5% EBITDA Adjusted 71.7 65.0 +10.3% Margin % 25.8% 25.1% +70bps © Amplifon S.p.A. October 29th, 2026
Page 9
Classification: public Data in €m (unless specified) Q3 2026 Q3 2025 ∆ 26/25 REVENUES 575.0 563.3 2.1% EBITDA Adj. 114.8 107.3 7.0% Margin % 20.0% 19.1% -- D&A (62.6) (64.6) 3.0% EBIT Adj. 52.2 42.8 21.9% Margin % 9.1% 7.6% -- NET FINANCIAL EXPENSES (15.8) (16.7) 5.8% PBT Adj. 36.4 26.0 39.8% Taxes (9.8) (6.8) -42.7% % on PBT 26.8% 26.2% -- Net Profit Adj. 26.6 19.2 38.7% Margin % 4.6% 3.4% -- EPS Adj. (€) 0.088 0.088 -0.8% Q3 2026 Financial results Excellent results across all P&L metrics with EBIT Adjusted up 22% (margin +150bps) and Net Profit Adjusted up 39% (margin +120 bps) Financial data excluding usual, infrequent or unrelated items (income and expenses) affecting the Group's operating/underlying performance. Definitions and reconciliation to IFRS Financial Statements Measures provided in Annex. 9 © Amplifon S.p.A. October 29th, 2026
Page 10
Classification: public Data in €m (unless specified) 9M 2026 9M 2025 ∆ 26/25 REVENUES 1,760.8 1,743.8 1.0% EBITDA Adj. 412.8 395.0 4.5% Margin % 23.4% 22.7% -- D&A (190.8) (195.9) 2.6% EBIT Adj. 222.0 199.1 11.5% Margin % 12.6% 11.4% -- NET FINANCIAL EXPENSES (45.5) (48.1) 5.4% PBT Adj. 176.5 151.0 16.9% Taxes (48.1) (41.2) -16.7% % on PBT 27.3% 27.3% -- Net Profit Adj. 128.2 109.6 16.9% Margin % 7.3% 6.3% -- EPS Adj. (€) 0.530 0.491 8.0% 9M 2026 Financial results Financial data excluding usual, infrequent or unrelated items (income and expenses) affecting the Group's operating/underlying performance. Definitions and reconciliation to IFRS Financial Statements Measures provided in Annex. 10 Strong results across all P&L metrics with EBIT Adjusted up 12% (margin +120bps) and Net Profit Adjusted up 17% (margin +100 bps) © Amplifon S.p.A. October 29th, 2026
Page 11
Classification: public Data in €m 9M 2026 Pro forma1 9M 2026 9M 2025 ∆ vs Pro forma Operating cash flow before repayment of lease liabilities adjusted2 245.8 245.8 223.9 21.8 Repayment of lease liabilities (102.4) (102.4) (100.6) (1.8) Operating cash flow adjusted2 143.4 143.4 123.3 20.0 Capex (net) (64.3) (64.3) (90.2) 25.9 Free cash flow adjusted2 79.1 79.1 33.2 45.9 Free cash flow 56.3 56.3 28.4 28.0 Acquisitions (net) 4.9 4.9 (58.6) 63.5 Cash provided by (used in) operating and investing activities 61.3 61.3 (30.2) 91.5 Cash provided by (used) financing activities (71.8) 376.4 (175.0) 103.2 Net cash flow for the period (10.5) 437.6 (205.2) 194.7 9M 2026 Financial results Outstanding cash generation, with free cash flow adjusted of €79m, up 139% vs. 9M 2025 Net financial position (opening date) (1,045.5) (1,045.5) (961.8) (83.7) Change in net financial position (10.5) 437.6 (205.2) 194.7 Effect of FX, HFS & Deconsolidation NFP 3.2 3.2 (7.7) 10.9 Net financial position (closing date) (1,052.8) (604.7) (1,174.7) 121.9 1. 9M 2026 pro forma excluding the impact of the equity raise via ABB completed on May 22nd, 2026 (net proceeds of €448.1m), which is intended to finance part of the cash consideration for the acquisition of GN Hearing 2. Adjusted from unusual, infrequent or unrelated items for €22.7m (€4.8m in 9M 2025) 11 © Amplifon S.p.A. October 29th, 2026
Page 12
Classification: public Leverage1 reduced to 1.85x, supported by strong cash generation and after €128m in Capex and dividends 9M 2026 Financial results 1. Data as of September 30th, 2026 pro forma, excluding the impact of the equity raise via ABB completed on May 22nd, 2026 (net proceeds of €448.1m), which is intended to finance part of the cash consideration for the acquisition of GN Hearing 2 Refers to the EBITDA recorded in the last 4 quarters determined excluding the fair value of the share-based payments and based only on the recurring business Data in €m 30/09/2026 Pro forma1 30/09/2026 31/12/2025 Liquidity (260.8) (709.0) (308.9) Short-term debt 668.2 668.2 366.4 Medium/long-term debt 645.4 645.4 988.0 Net financial debt 1,052.8 604.7 1,045.5 Lease liabilities 477.0 477.0 486.3 Total financial debt & lease liabilities 1,529.8 1,081.7 1,531.8 Total net equity 1,537.0 1,537.0 998.5 Net debt/EBITDA2 1.85x 1.06x 1.92x Net debt/Equity 0.69x 0.39x 1.05x 12 © Amplifon S.p.A. October 29th, 2026
Page 13
Classification: public 2026 Outlook Strong momentum continues During 2025, we implemented meaningful initiatives and invested substantially to accelerate future revenue growth and structurally enhance profitability In 9M 2026, these initiatives and investments delivered tangible results, driving improvements in both organic growth and profitability Looking ahead to 2026, we confirm our expectations for: Global market demand growth in the region of +3% Continuedoutperformancein our key individualmarkets,drivingmarketshare gains,with organicgrowthabove+3% A material increase in Adjusted EBITDA margin, in the region of +100 bps Prospective GN Hearing acquisition: integration planning is progressing well and is fully on track to ensure Day 1 readiness following the necessary regulatory approvals Looking beyond 2026, we are highly confident and excited about our strong prospects for profitable growth, further strengthened by the transformational opportunity created by the GN Hearing acquisition 13 © Amplifon S.p.A. October 29th, 2026
Page 14
Annex
Page 15
Classification: public Data in €m (unless specified) Q3 2026 Q3 2025 ∆ 26/25 REVENUES 575.0 563.3 2.1% EBITDA 103.6 103.5 0.1% Margin % 18.0% 18.4% -- ORDINARY D&A (62.8) (66.6) 5.6% PPA AMORTIZATION (11.5) (12.6) 9.0% EBIT 29.3 24.3 20.4% Margin % 5.1% 4.3% -- NET FINANCIAL EXPENSES (16.2) (17.1) 5.2% PBT 13.0 7.2 81.6% Taxes (3.6) (0.8) -340.9% % on PBT 27.3% 11.3% -- Net Profit 9.4 6.3 48.7% Margin % 1.6% 1.1% -- EPS (€) 0.028 0.030 -7.2% Q3 2026 Reported financials 15 © Amplifon S.p.A. October 29th, 2026
Page 16
Classification: public Data in €m (unless specified) 9M 2026 9M 2025 ∆ 26/25 REVENUES 1760.8 1743.8 1.0% EBITDA 380.6 390.4 -2.5% Margin % 21.6% 22.4% -- ORDINARY D&A (191.3) (199.3) 4.0% PPA AMORTIZATION (34.8) (37.9) 8.1% EBIT 154.5 153.3 0.8% Margin % 8.8% 8.8% -- NET FINANCIAL EXPENSES (65.0) (47.8) -35.8% PBT 89.6 105.4 -15.1% Taxes (30.9) (30.9) -0.1% % on PBT 34.5% 29.3% -- Net Profit 58.4 74.4 -21.5% Margin % 3.3% 4.3% -- EPS (€) 0.242 0.333 -27.5% 9M 2026 Reported financials 16 © Amplifon S.p.A. October 29th, 2026
Page 17
Classification: public Alternative Performance Measures -adjustments Alternative Performance Measures exclude the impact of unusual, infrequent or unrelated items to the normal course of business including Transaction and integration costs for acquisitions and changes in earn-out Charges and write-off related to reorganization, efficiency projects, and changes to the top management Gain and loss on disposal of assets & businesses, write-off and revaluation of fixed assets PPA amortization Financial income (loss) related to inflation accounting and Fair Value changes resulting from modifications and/or non- cash accretion in financial liabilities Other unusual, infrequent or unrelated income and expenses above an amount of €1m in a quarter, or above €2m across multiple quarters Fiscal effect on adjustments & other fiscal adjustments 17 © Amplifon S.p.A. October 29th, 2026
Page 18
Classification: public Q3 2026 Reconciliation to consolidated financial statements 1. Other unusual, infrequent or unrelated income and expenses above an amount of €1m in a quarter, or above €2m across multiple quarters 18 Data in €m EBITDA EBIT Net Profit IFRS Financial Statements Measures (as reported) 103.6 29.3 9.4 Transaction and integration costs for the acquisition of GN Hearing 5.0 5.0 5.0 Transaction and integration costs for other acquisitions and changes in earn-out 0.2 0.2 0.2 Chargesand write-off related to reorganization,efficiencyprojects,and changes to the top management 3.6 3.6 3.6 Gain and loss on disposal of assets & businesses, write-off and revaluation of fixed assets 0.2 0.3 0.7 PPA amortization - 11.5 11.5 Financial income (loss) related to inflation accounting and Fair Value changes resulting from modifications and/or non-cash accretion in financial liabilities - - 0.5 Other1 2.2 2.2 1.8 Total adjustments before tax 11.2 22.9 23.4 Fiscal effect on adjustments & other fiscal adjustments - - (6.2) Total adjustments 11.2 22.9 17.2 Adjusted Measures 114.8 52.2 26.6 © Amplifon S.p.A. October 29th, 2026
Page 19
Classification: public Data in €m EBITDA EBIT Net Profit IFRS Financial Statements Measures (as reported) 103.5 24.3 6.3 Transaction and integration costs for the acquisition of GN Hearing - - - Transaction and integration costs for acquisitions and changes in earn-out 0.2 0.2 0.2 Chargesand write-off related to reorganization,efficiencyprojects,and changes to the top management 3.7 5.6 5.6 Gain and loss on disposal of assets & businesses, write-off and revaluation of fixed assets (0.1) (0.0) (0.0) PPA amortization - 12.6 12.6 Financial income (loss) related to inflation accounting and Fair Value changes resulting from modifications and/or non-cash accretion in financial liabilities - - 0.4 Other1 - - (0.0) Total adjustments before tax 3.9 18.5 18.9 Fiscal effect on adjustments & other fiscal adjustments - - (6.0) Total adjustments 3.9 18.5 12.9 Adjusted Measures 107.3 42.8 19.2 Q3 2025 Reconciliation to consolidated financial statements 19 1. Other unusual, infrequent or unrelated income and expenses above an amount of €1m in a quarter, or above €2m across multiple quarters © Amplifon S.p.A. October 29th, 2026
Page 20
Classification: public 9M 2026 Reconciliation to consolidated financial statements 1. Other unusual, infrequent or unrelated income and expenses above an amount of €1m in a quarter, or above €2m across multiple quarters 20 Data in €m EBITDA EBIT Net Profit IFRS Financial Statements Measures (as reported) 380.6 154.5 58.4 Transaction and integration costs for the acquisition of GN Hearing 16.9 16.9 16.9 Transaction and integration costs for other acquisitions and changes in earn-out (0.2) (0.2) (0.2) Chargesand write-off related to reorganization,efficiencyprojects,and changes to the top management 11.6 11.8 11.8 Gain and loss on disposal of assets & businesses, write-off and revaluation of fixed assets 0.3 0.6 20.6 PPA amortization - 34.8 34.8 Financial income (loss) related to inflation accounting and Fair Value changes resulting from modifications and/or non-cash accretion in financial liabilities - - 1.6 Other1 3.7 3.7 1.5 Total adjustments before tax 32.2 67.5 86.9 Fiscal effect on adjustments & other fiscal adjustments - - (17.2) Total adjustments 32.2 67.5 69.7 Adjusted Measures 412.8 222.0 128.2 © Amplifon S.p.A. October 29th, 2026
Page 21
Classification: public Data in €m EBITDA EBIT Net Profit IFRS Financial Statements Measures (as reported) 390.4 153.3 74.4 Transaction and integration costs for the acquisition of GN Hearing - - - Transaction and integration costs for acquisitions and changes in earn-out (0.6) (0.6) (0.6) Chargesand write-off related to reorganization,efficiencyprojects,and changes to the top management 5.1 8.4 8.4 Gain and loss on disposal of assets & businesses, write-off and revaluation of fixed assets - 0.1 0.1 PPA amortization - 37.9 37.9 Financial income (loss) related to inflation accounting and Fair Value changes resulting from modifications and/or non-cash accretion in financial liabilities - - 1.6 Other1 - - (1.9) Total adjustments before tax 4.5 45.8 45.5 Fiscal effect on adjustments & other fiscal adjustments - - (10.4) Total adjustments 4.5 45.8 35.2 Adjusted Measures 395.0 199.1 109.6 9M 2025 Reconciliation to consolidated financial statements 21 1. Other unusual, infrequent or unrelated income and expenses above an amount of €1m in a quarter, or above €2m across multiple quarters © Amplifon S.p.A. July 30th, 2026
Page 22
I nv e st o r R e l a t io ns & S ust a ina b il it y C o nt a c t s FRANCESCA RAMBAUDI Investor Relations & Sustainability Sr Director Tel: +39 02 5747 2261 francesca.rambaudi@amplifon.com AMANDA HART GIRALDI Investor Relations Manager Tel: +39 02 5747 2317 amanda.giraldi@amplifon.com OLGA LEPECHKINA Assistant Tel: +39 02 5747 2542 olga.lepechkina@amplifon.com